



PATENT / DOCKET NO.: 6643R2US
CUSTOMER NO.: 27683

CJC
[Signature]

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	§	Serial No. 09/676,034
James B. Camden, et al.	§	
	§	Filed: September 29, 2000
U.S. Patent: 6,864,275 B1	§	
	§	Group Art Unit: 1614
Issued: March 8, 2005	§	
	§	Examiner: C. Delacroix-Muirheid
For: Compounds and Methods for Use	§	
Thereof in the Treatment of Cancer	§	

**REQUEST FOR EXPEDITED ISSUANCE OF CERTIFICATE OF CORRECTION
UNDER 35 § USC 254**

Mail Stop Certificate of Correction Branch
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Applicants hereby request expedited issuance of a Certificate of Correction to correct a mistake in the above-identified patent as set forth on the attached form PTO/SB/44. Provided as Attachment A is a copy of the Response to Office Action mailed February 2, 2004, with Claim 1 (issued as Claim 1) as previously presented.

Since the mistake was incurred through the fault of the Patent and Trademark Office, no fee is necessary.

Respectfully submitted,

Gloria L. Norberg

Gloria L. Norberg
Registration No. 36,706

Date: April 6, 2005
Haynes and Boone, LLP
901 Main Street, Suite 3100
Dallas, TX 75202-3789
(512) 867-8528
(512) 200-0853 - fax

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Certificate of Correction Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450	
Date:	<u>4/6/05</u>
	<u>NISHI PASARVA</u>
Signed:	<u>[Signature]</u>

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

PATENT NO. : 6,864,275
DATED : March 8, 2005
INVENTOR(S) : James Berger Camden

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

At column 31, line 7 (claim 1) delete "alkoxyalkly" and replace with --alkoxyalkyl--;

MAILING ADDRESS OF SENDER:

Haynes and Boone, LLP
901 Main Street, Suite 3100
Dallas, TX 75202

PATENT NO. 6,864,275 B1

No. of additional copies



This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PATENT / DOCKET NO.: 6643R2
CUSTOMER NO.: 27683

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

James Berger Camden, et al.

Serial No.: 09/676,034

Filed: September 29, 2000

For: Compounds and Methods for Use
Thereof In the Treatment of Cancer
(as amended)

Group Art Unit: 1614

Examiner: Delacroix Muirheid, C.

Mail Stop Non-Fee Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Transmitted herewith is an Amendment; Response to Office
Action Mailed February 2, 2004.

I hereby certify that this paper is being transmitted by facsimile to
the Patent and Trademark Office on the date shown below:

Fax Number: (703) 872-9306

Julie Schwartz
Julie Schwartz

SIGNATURE

04/29/04
DATE OF TRANSMISSION

[X] No additional fee is required.

The fee has been calculated as shown below:

	(Col. 1)		(Col. 2)		(Col. 3)	SMALL ENTITY			OTHER THAN A SMALL ENTITY	
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR		PRESENT EXTRA	RATE	ADDIT FEE.	OR	RATE	ADDIT. FEE
TOTAL	19	minus	23	=	0	x 9	\$	OR	x 18	\$0
INDEP	2	minus	3	=	0	x 42	\$	OR	x 84	\$0
[]	FIRST PRESENTATION OF MULTIPLE DEP. CLAIM					+ 140	\$	OR	+ 280	\$0
						TOTAL	\$	OR	TOTAL	\$0

* If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.

** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.

*** If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.

The "Highest Number Previously Paid For" (Total or Independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment or the number of claims originally filed.

[] Please charge Haynes and Boone, LLP Deposit Account No. 08-1394 in the amount of _____.

[] A check in the amount of \$ _____ is attached.

[] The Commissioner is hereby petitioned under 37 CFR § 1.136(a) to grant any extension of time needed for timely response to the Office Action dated in the above-identified application to preserve pendency of said application.

[X] The Commissioner is hereby authorized to charge payment of any fees associated with this communication or credit any overpayment to Haynes and Boone, LLP Deposit Account No. 08-1394.

[] Any additional filing fees under 37 C.F.R. § 1.16 for the presentation of extra claims.

[X] Any patent application processing fees under 37 C.F.R. § 1.17.

Respectfully submitted,


Gloria L. Norberg

Gloria L. Norberg

Registration. No. 36,706

Date: *April 29, 2004*
HAYNES AND BOONE, LLP
901 Main Street, Suite 3100
Dallas, Texas 75202-3789
Telephone: 512-867-8528
Facsimile: 210-200-0853

bcc: Alfred "Bo" Statham
Patrick L. Jones, Ph.D., MBA



PATENT / DOCKET NO.: 6643R2
CUSTOMER NO.: 27683

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	§	
James B. Camden, et al.	§	Examiner: Delacroix Muirheid, C.
	§	
Serial No.: 09/676,034	§	Group Art Unit: 1614
	§	
Filed: September 29, 2000	§	
	§	
For: Compounds and Methods for Use	§	
Thereof In the Treatment of Cancer	§	
(as amended)	§	

Mail Stop Non-Fee Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

AMENDMENT; RESPONSE TO OFFICE ACTION
MAILED FEBRUARY 2, 2004

The present paper is submitted as a complete response to the Official Action mailed February 2, 2004 having a shortened statutory period of response of three months, to May 2, 2004. The present paper is timely filed since this paper is being filed prior to or on the three-month date; however, should an extension of time be required, this paper is such a request. No fees are believed due for the filing of the present document, however, should any fees be due, the Commissioner is authorized to deduct said fees under 37 C.F.R. §§ 1.16 to 1.21 from Haynes and Boone Deposit Account No. 08-1394.


Listing of Claims section begins on page 2 of this paper.

Remarks section begins on page 6 of this paper.

Listing of Claims

The following listing of claims will replace all prior versions, and listings, of claims in the application.

1. (Previously amended) A method for treating carcinoma, sarcoma, or lymphoma susceptible to treatment in a warm-blooded animal comprising administering to the warm-blooded animal a therapeutically effective amount of a compound of the following formula **A-1**:



A-1

wherein,

R is $-\text{CONR}_1\text{R}_2$, $-\text{OCOR}_1$ or $-\text{NHCOR}_1$;


R₁ is alkyl, haloalkyl, hydroxyalkyl, alkenyl, haloalkenyl, cycloalkyl, cycloalkalkyl, heterocycloalkyl, heterocycloalkalkyl, substituted or unsubstituted phenyl, substituted or unsubstituted phenylamino, substituted or unsubstituted benzyl, alkoxyalkyl, poly(alkoxy)alkyl, hydroxyalkoxyalkyl, hydroxypoly(alkoxy)alkyl, haloalkoxyalkyl, halopoly(alkoxy)alkyl, or aminoalkyl; and

R₂ is hydrogen or alkyl.

2. (Previously amended) A method according to claim 1 wherein the compound is in the form of a pharmaceutically acceptable salt thereof.
3. (Original) A method according to claim 2 wherein said pharmaceutically acceptable salt is hydrochloride salt.

4. (Previously amended) A method according to claim 1 wherein the compound is in the form of a prodrug thereof.
5. (Cancelled)
6. (Original) A method according to claim 1 wherein R is $-\text{OCOR}_1$.
7. (Original) A method according to claim 6 wherein R_1 is alkyl or substituted or unsubstituted phenyl.
8. (Original) A method according to claim 1 wherein said compound is micronized and is suitable for administering to said warm-blooded animal by injection.
9. (Original) A method according to claim 1 wherein said compound is administered in an amount of from 10 mg/kg body weight to 10,000 mg/kg body weight.
10. (Original) A method according to claim 1 wherein said compound is administered orally, enterically, intravenously, peritoneally, or by injection.
11. (Original) A method according to claim 1 wherein said compound is administered in a pharmaceutically acceptable carrier.
12. (Currently Amended) A method according to claim 1 wherein the method is for treating said cancer ~~is a carcinoma~~.
13. (Cancelled)
14. (Previously amended) A method according to claim 12 wherein said carcinoma is melanoma.
15. (Previously amended) A method according to claim 12 wherein said carcinoma is colon cancer.
16. (Previously amended) A method according to claim 12 wherein said carcinoma is breast cancer.

17. (Previously amended) A method according to claim 12 wherein said carcinoma is lung cancer.
18. (Previously amended) A method according to claim 12 wherein said carcinoma is pancreatic cancer.
19. (Previously amended) A method according to claim 12 wherein said carcinoma is ovarian cancer.
20. (Previously amended) A method according to claim 12 wherein said carcinoma is prostate cancer.
21. (Cancelled)
22. (Cancelled)
23. (Cancelled)
24. (Previously added) A method for treating leukemia susceptible to treatment in a warm-blooded animal comprising administering to the warm-blooded animal a therapeutically effective amount of a compound of the following formula A-1:



A-1

wherein,

R is $-\text{OCOR}_1$; and

R_1 is alkyl, haloalkyl, hydroxyalkyl, alkenyl, haloalkenyl, cycloalkyl, cycloalkalkyl, heterocycloalkyl, heterocycloalkalkyl, substituted or unsubstituted phenyl, substituted or unsubstituted phenylamino, substituted or unsubstituted benzyl, alkoxyalkyl,

poly(alkoxy)alkyl, hydroxyalkoxyalkyl, hydroxypoly(alkoxy)alkyl, haloalkoxyalkyl, halopoly(alkoxy)alkyl, or aminoalkyl.

REMARKS

I. Status of the Claims

Claim 12 is amended. Claims 1-4, 6-12, 14-20, and 24 are pending.

II. Rejection of Claims 12 and 14-20 under 35 USC § 112, Second Paragraph

Claims 12 and 14-20 were rejected under 35 U.S.C §112, second paragraph, for insufficient antecedent basis for the limitation "said cancer."


Response

Claim 12 is amended to recite proper antecedent basis to Claim 1. Therefore, Claim 12 is believed patentable. Claims 14-20 are dependent upon Claim 1 and therefore are believed to be patentable also. Applicant respectfully requests that the rejection under 35 U.S.C §112, second paragraph, be withdrawn.

IV. Conclusion

All matters of the Office Action have been addressed. Reconsideration and an early indication of the allowance of the pending claims are earnestly requested. Should the Examiner have any questions, comments or suggestions that would expedite the prosecution of the present case to allowance, Applicants' representative, Gloria L. Norberg, earnestly requests a telephone conference at (512) 867-8528.

Respectfully submitted,



Gloria L. Norberg
Agent for Applicant
Reg. No. 36,706

Date: April 29, 2004
HAYNES AND BOONE, LLP
901 Main Street, Suite 3100
Dallas, Texas 75202-3789
Telephone: 512-867-8528
Facsimile: 210-200-0853

I hereby certify that this paper is being transmitted by facsimile to the Patent and Trademark Office on the date shown below:	
Fax Number: (703) 872-9306	
<u>Julie Schwartz</u>	
Julie Schwartz	
<u>Julie Schwartz</u>	
SIGNATURE	
<u>04/29/04</u>	
DATE OF TRANSMISSION	



Auto-Reply Facsimile Transmission



TO: Fax Sender at 512 867 8470

Fax Information
 Date Received: 4/29/2004 3:24:37 PM [Eastern Daylight Time]
 Total Pages: 8 (including cover page)

ADVISORY: This is an automatically generated return receipt confirmation of the facsimile transmission received by the Office. Please check to make sure that the number of pages listed as received in Total Pages above matches what was intended to be sent. Applicants are advised to retain this receipt in the unlikely event that proof of this facsimile transmission is necessary. Applicants are also advised to use the certificate of facsimile transmission procedures set forth in 37 CFR 1.8(a) and (b), 37 CFR 1.6(f). Trademark Applicants, also see the Trademark Manual of Examining Procedure (TMEP) section 306 et seq.

Received
 Cover
 Page

=====>

04/29/2004 14:27 FAX 512 867 8470		HAYNES & BOONE		0001	
haynes boone Are you changing? www.haynesboone.com					
HAYNES AND BOONE, LLP Fax Transmittal					
DATE: April 29, 2004		Total Pages Including Cover: 8			
TO:	Examiner Delacroix-Muirheid	Company:	United States Patent and Trademark Office		
Fax #:	703-872-9306	Phone #:	703-308-3227		
Client/Matter #: 6643R2 (34407.38)					
FROM:	Dr. Gloria L. Norberg	Haynes and Boone, LLP			
I.D. #:	80697	901 Main Street, Suite 3100 Dallas, Texas 75202-3789			
Direct Phone #:	(512) 867-8528				
Direct Fax #:	(512) 867-8632	Main Phone #:	(512) 867-8400		
E-Mail:	gloria.norberg@haynesboone.com	Main Fax #:	(210) 200-0853		
Should you have any problems with this transmittal, please call: 512-867-8522					
MESSAGE:					
U.S. Application No. 09/676,034, Filed: September 29, 2000					
Title: Compounds and Methods for Use Thereof in the Treatment of Cancer (as amended)					
Attorney Docket No.: 6643R2					
Examiner Delacroix-Muirheid.					
Attached please find a Transmittal Letter, and an Amendment; Response to Office Action mailed February 2, 2004.					
Entry of these papers in the above reference application is courteously solicited. Any question regarding this matter should be directed to the undersigned.					
Gloria Norberg Reg. No.: 36,706					
<small>Confidentiality Note: The information contained in this facsimile message is privileged and confidential and is intended only for the use of the addressee. The term "privileged and confidential" includes, without limitation, attorney-client privileged communications, attorney work product, trade secrets, and any other proprietary information. Nothing in this facsimile is intended by the attorney or the client to constitute a waiver of the confidentiality of this message. If the reader of this message is not the intended recipient, or employee/agent of the intended recipient, you are hereby notified that any duplication, or distribution of this communication is unauthorized. If you have received this message in error, please notify us by telephone immediately so that we can arrange for the return of the original document to us at no cost to you.</small>					
PAGE 18 * RCVD AT 4/29/2004 3:24:37 PM (Eastern Daylight Time) * SVR:USPTO-EFAXF-15 * DHIS:8728306 * CSID:512 867 8470 * DURATION (mm:ss):02:12					